$GOSS news

The latest GOSS stock news: headlines, filings, AI summaries and sentiment for $GOSS, updated around the clock.

• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · November 10, 2026, 21:50 UTC
• Gossamer Bio, Inc. - 10-Q Filing SEC EDGAR · November 10, 2026, 21:49 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · October 28, 2026, 20:02 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 28, 2026, 20:03 UTC
• Gossamer Bio Submits NDA for Seralutinib in Pulmonary Arterial Hypertension Seeking Alpha · September 23, 2026, 22:16 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 23, 2026, 20:06 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 16, 2026, 20:06 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 11, 2026, 12:02 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 9, 2026, 13:02 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · September 3, 2026, 20:03 UTC
• Gossamer Announces Up to $250M Financing with Conditional Tranches Yahoo Finance · August 27, 2026, 19:59 UTC
• Gossamer Bio Secures Up to $250M Financing for Seralutinib Development Yahoo Finance · August 24, 2026, 10:15 UTC
• Gossamer Bio Shares Rise on FDA Update and Regained Rights to Seralutinib Yahoo Finance · July 27, 2026, 13:33 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · July 27, 2026, 20:02 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · July 15, 2026, 10:07 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · June 5, 2026, 10:03 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · June 5, 2026, 10:01 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · June 2, 2026, 12:02 UTC
• Gossamer Bio Targets NDA Filing for Seralutinib in September 2026 with Potential Approval by Q3 2027 Seeking Alpha · May 18, 2026, 22:11 UTC
• Gossamer Bio Outlines Regulatory and Financial Plans in Q1 Earnings Call Yahoo Finance · May 18, 2026, 13:05 UTC
• Gossamer Bio Reports Q1 GAAP EPS of -$0.20, Revenue Exceeds Expectations Seeking Alpha · May 18, 2026, 11:03 UTC
• Gossamer Bio, Inc. - 8-K Filing SEC EDGAR · May 18, 2026, 11:07 UTC
• Class Action Lawsuit Filed Against Gossamer Bio, Inc. Over Failed Clinical Trial Results PR Newswire · April 30, 2026, 23:42 UTC
• Gossamer Bio Faces Securities Fraud Lawsuit Over Alleged Placebo Risk Concealment PR Newswire · April 23, 2026, 13:00 UTC
• Gossamer Bio Announces Failed Phase 3 Trial Results, Leading to Sharp Stock Decline Auto-Fetched Original Sources · March 31, 2026, 21:27 UTC
• Gossamer Bio Shareholders May Pursue Class Action Over Alleged Misleading Statements PR Newswire · April 21, 2026, 13:00 UTC
• Class Action Lawsuit Filed Against Gossamer Bio, Inc. Over Failed Clinical Trial Results PR Newswire · April 16, 2026, 14:00 UTC